WHO ICTRP trial
(Withdrawn by researcher) Prospective study of camrelizumab in combination with…
ChiCTR2300070894 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2300070894 |
|---|---|
| Public title | (Withdrawn by researcher) Prospective study of camrelizumab in combination with chemotherapy for the neoadjuvant treatment of resectable/potentially resectable locally advanced esophageal squamous cell carcinoma |
| Scientific title | Prospective study of camrelizumab in combination with chemotherapy for the neoadjuvant treatment of resectable/potentially resectable locally advanced esophageal squamous cell carcinoma |
| Primary sponsor | People’s Hospital of Yangzhong |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 4 |
| Countries | China |
| Conditions | Esophageal squamous cell carcinoma |
| Interventions | Group A:Patients were treated with 2 cycles of the following drugs intravenously: camrelizumab (200 mg on day 1 every 3 weeks), nab-paclitaxel (260 mg/m2 on day 1 every 3 weeks), and carboplatin (area under the curve of 5 mg/mL/min on day 1… |
| Registration date | Apr 26, 2023 |
| Target size | Group A:30;Group B:30 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: